Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

Published Date: 18 Mar 2024

In a full day of meetings, the FDA advisory panel will assess the evidence for cilta-cel and ide-cel.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

De-escalation Misses the Mark in Inflammatory Breast Cancer

2.

10-year study shows tomosynthesis improves breast cancer detection

3.

Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients

4.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

5.

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot